menu ☰
menu ˟

Thyroid hormone receptor agonist improves liver fat, lipoproteins in NASH

07 Dec 2017
Madrigal Pharmaceuticals announced positive interim results from a phase 2 clinical trial of MGL-3196 for reducing liver fat in patients with nonalcoholic steatohepatitis, according to a press release and company presentation.Paul A. Friedman Rebecca...

Click here to view the full article which appeared in Endocrinology

IPH Logo